[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.75.207. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1991

MK-507 (L-671,152), a Topically Active Carbonic Anhydrase Inhibitor, Reduces Aqueous Humor Production in Monkeys

Author Affiliations

From the Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY (Drs Wang, Serle, and Podos); and Merck Sharp & Dohme Research Laboratories, West Point, Pa (Dr Sugrue).

Arch Ophthalmol. 1991;109(9):1297-1299. doi:10.1001/archopht.1991.01080090123036
Abstract

• An investigation was carried out to determine the mechanism by which MK-507 (L-671,152), a water-soluble inhibitor of human carbonic anhydrase II in vitro, reduces intraocular pressure when applied topically to monkey eyes. Intraocular pressure, tonographically measured outflow facility, and fluorophotometrically determined aqueous humor flow were measured before and after therapy in eight normal cynomolgus monkeys. Fifty microliters of 2% MK-507 was instilled in one eye and diluent in the contralateral eye. Baseline values for intraocular pressure, outflow facility, and aqueous humor flow were similar in the drug-treated and diluent-treated control eyes. After therapy, intraocular pressure was significantly (P<.05) reduced from 1 to 7 hours (eg, 14.0±1.0 and 15.9±0.9 mm Hg [mean±SEM], treated and control eyes, respectively, at 3 hours). Outflow facility was not significantly (P>.40) changed at 3 hours, and aqueous humor flow measured over 5 hours was significantly (P<.05) reduced (38%) in treated (0.9±0.1 μL/min) as compared with control eyes (1.5±0.1 μL/min). The results suggest that MK-507 reduces intraocular pressure by decreasing aqueous humor production.

References
1.
Becker B.  Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox . Am J Ophthalmol . 1954;37:13-15.
2.
Grant B, Middleton WH.  Long-term acetazolamide administration in therapy of glaucoma . Arch Ophthalmol . 1954;51:735-739.Article
3.
Maren TH, Jankowska L, Sanyal G, Edelhauser HF.  The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect of aqueous humor secretion . Exp Eye Res . 1983;36:457-480.Article
4.
Stein A, Pinke R, Krupin T, et al.  The effect of topically administered carbonic anhydrase inhibitors on aqueous dynamics in rabbits . Am J Ophthalmol . 1983;95:222-228.Article
5.
Lewis RA, Schoenwald RD, Barfknecht CF, Phelps CD.  Aminozolamide gel: a trial of topical carbonic anhydrase inhibitor in ocular hypertension . Arch Ophthalmol . 1986;104:842-844.Article
6.
Kalina PH, Shetlar DJ, Lewis RA, Kullerstrand LJ, Brubaker RF.  6-Amino-2-benzothiazole-sulfonamide: the effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye . Ophthalmology . 1988;95:772-777.Article
7.
Bar-Ilan A, Pessah NI, Maren TH.  Ocular hypotensive activity and disposition of the topical carbonic anhydrase inhibitor 6-hydroxy-benzo[b]thiophene-2-sulfonamide, L-650,719, in the rabbit . J Ocul Pharmacol . 1989;5:99-110.Article
8.
Werner EB, Gerber DS, Yolanda JY.  Effect of a topical carbonic anhydrase inhibitor, 6-hydroxybenzo[b]thiophene-2-sulfonamide, on intraocular pressure in normotensive subjects . Can J Ophthalmol . 1987;22:316-319.
9.
Sugrue MF, Gautheron P, Grove J, et al.  MK-927: a topically active ocular hypotensive carbonic anhydrase inhibitor . J Ocul Pharmacol . 1990;6:9-21.Article
10.
Maren TH, Bar-Ilan A, Conroy CW, Brechue WF.  Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical route . Exp Eye Res . 1990;50:27-36.Article
11.
Wang RF, Serle JB, Podos SM, Sugrue MF.  The effect of MK-927, a topical carbonic anhydrase inhibitor, on IOP in glaucomatous monkeys . Curr Eye Res . 1990;9:163-168.Article
12.
Lippa EA, Von Denffer HA, Hofmann HM, Brunner-Ferber FL.  Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor . Arch Ophthalmol . 1988;106:1694-1696.Article
13.
Pfeiffer N, Hennekes R, Lippa EA, Grehn F, Garus H, Brunner-Ferber FL.  A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients . Br J Ophthalmol . 1990;74:405-408.Article
14.
Bron AM, Lippa EA, Hofmann HM, et al.  MK-927: a topically effective carbonic anhydrase inhibitor in patients . Arch Ophthalmol . 1989;107:1143-1146.Article
15.
Serle JB, Lustgarten JS, Lippa EA, Camras CB, Panebianco DL, Podos SM.  MK-927, a topical carbonic anhydrase inhibitor . Arch Ophthalmol . 1990;108:838-841.Article
16.
Higginbotham EJ, Kass MA, Lippa EA, Batenhorst RL, Panebianco DL, Wilensky JT.  MK-927: a topical carbonic anhydrase inhibitor, dose response and duration of action . Arch Ophthalmol . 1990;108:65-68.Article
17.
Serle JB, Lustgarten JS, Lippa EA, et al.  Six-week study of 2% MK-927 BID in ocular hypertensives . Ophthalmology . 1990;97( (suppl) ):124.
18.
Diestelhorst M, Bechetoille A, Lippa EA, Brunner-Ferber FL, Krieglstein GK.  Zur Stereospezifität der Augendrucksenkung eines lokal applizierten karboanhydrase-hemmers . Fortschr Ophthalmol . 1990;87:131-133.
19.
Bron A, Lippa EA, Gunning F, et al. Multiple-dose efficacy comparison of two topical carbonic anhydrase inhibitors MK-417 and MK-927. Arch Ophthalmol. In press.
20.
Sugrue MF, Mallorga P, Schwam H, Baldwin JJ, Ponticello GS.  A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals . Curr Eye Res . 1990;9:607-615.Article
21.
Wang RF, Serle JB, Podos SM, Sugrue MF.  The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys . Arch Ophthalmol . 1990;108:511-513.Article
22.
Yablonski ME, Cook DJ, Gray J.  A fluorophotometric study of the effect of argon laser trabeculoplasty on aqueous humor dynamics . Am J Ophthalmol . 1985;99:579-582.
23.
Becker B.  Friedenwald Memorial Lecture: carbonic anhydrase and the formation of aqueous humor . Am J Ophthalmol . 1959;47:342-361.
24.
Bar-Ilan A, Pessah NI, Maren TH.  The effects of carbonic anhydrase inhibitors on aqueous humor chemistry and dynamics . Invest Ophthalmol Vis Sci . 1984;1198-1205.
25.
Dailey RA, Brubaker RF, Bourne WM.  The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects . Am J Ophthalmol . 1981;93:232-237.
26.
Buclin T, Lippa EA, Biollaz J, et al.  Absence of metabolic effects of the novel topically active carbonic anhydrase inhibitor MK-927 and its S-isomer during a two-week ocular administration . Eur J Clin Pharmacol . 1989;36( (suppl) ):5-46.Article
×